Shanghai Pharmaceuticals Holdings ADR (SHPMY) Stock Price & News

Shanghai Pharmaceuticals is a private-sector Chinese pharmaceutical company. The organization develops and distributes pharmaceutical products and operates in domestic and international markets. Shanghai Pharma is the largest pharmaceutical and the first A+H listed company in China to be dual-listed by Shanghai and Hong Kong Stock Exchanges. As of 2020, the company made its presence to the Global Fortune 500 list with the ranking of 473, overall and 124 among 21 other Chinese companies on the list. Shanghai Pharmaceuticals was founded in 1994 and is headquartered in Shanghai. As an investment holding company, it is actively engaged in research, manufacturing and distribution of pharmaceutical and healthcare products in China, that develops and distributes traditional Chinese and chemical drugs, chemical, biochemical and healthcare goods that are applied in various therapeutic fields, including immunoregulation and anti-cancer, immune system and digestion, cardiovascular and anti-infection, nervous system and mental disorder. Wikipedia

About Shanghai Pharmaceuticals Holdings ADR

CEO-

Employees48,6 мың

Founded1994 ж. 18 қаң.

Headquarters-

SectorHealth care provider

Websitesphchina.com

All values in CNY	2025 ж. қыр.	2025 ж. жел.	2026 ж. нау.	2026 ж. мау.
Revenue	73,48 млрд	68,51 млрд	75,26 млрд	72,21 млрд
Cost of goods sold	66,03 млрд	60,55 млрд	67,17 млрд	64,09 млрд
Cost of revenue	66,03 млрд	60,55 млрд	67,17 млрд	64,09 млрд
Research and development expenses	556,53 млн	824,53 млн	468,22 млн	502,64 млн
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	4,70 млрд	4,97 млрд	4,59 млрд	4,65 млрд
Operating expense	5,58 млрд	5,91 млрд	5,47 млрд	5,55 млрд
Total operating expenses	71,60 млрд	66,47 млрд	72,63 млрд	69,64 млрд
Operating income	1,88 млрд	2,04 млрд	2,63 млрд	2,57 млрд
Other non operating income	-84,84 млн	-63,65 млн	-47,88 млн	-7,43 млн
EBT including unusual items	1,48 млрд	1,52 млрд	2,42 млрд	3,21 млрд
EBT excluding unusual items	1,61 млрд	1,44 млрд	2,27 млрд	3,03 млрд
Income tax expense	485,91 млн	534,14 млн	569,09 млн	720,64 млн
Effective tax rate	32,89%	35,10%	23,52%	22,43%
Other operating expenses	129,62 млн	271,29 млн	132,16 млн	186,62 млн
Net income	688,20 млн	577,49 млн	1,42 млрд	2,09 млрд
Net profit margin	0,94%	0,84%	1,88%	2,89%
Earnings per share	-	-	-	-
Interest and investment income	206,57 млн	-	38,70 млн	873,52 млн
Interest expense	-393,02 млн	-470,36 млн	-347,64 млн	-358,39 млн
Net interest expenses	-186,45 млн	-470,36 млн	-308,94 млн	515,13 млн
Depreciation and amortization charges	-	-	-	-
EBITDA	2,26 млрд	2,54 млрд	3,12 млрд	3,07 млрд
Gain or loss from assets sale	39,99 млн	-157,15 млн	-	-179,70 млн

Finance

Ask anything